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The surface glycoprotein gp82, expressed in the insect-stage metacyclic trypomastigotes of Trypanosoma
cruzi, has been implicated in mammalian cell invasion. Here we have characterized the cell adhesion site of
gp82 by using recombinant proteins and synthetic peptides based on gp82. The recombinant protein Del-4/8,
lacking 65 amino acids of gp82 central domain (at positions 257 to 321), was virtually devoid of cell-binding
activity and lacked the ability to inhibit parasite invasion, in contrast to J18, the construct containing the
full-length gp82 sequence (amino acids 1 to 516). Constructs with shorter deletions, i.e., Del-4 (deleted from
257 to 271) and Del-8 (deleted from 293 to 321), bound to target cells to a significantly lesser degree than did
J18. The sites deleted in recombinant proteins Del-4 and Del-8 contained acidic amino acids critical for cell
adhesion. Thus, the cell-binding capacity of protein Del-E/D, lacking the glutamic acid (259/260) and aspartic
acid (303/304) pairs, was negligible, as was its capacity to inhibit parasite internalization. Of a set of synthetic
peptides spanning the gp82 central domain, a 22-mer hybrid peptide, p4/8, formed by two noncontiguous
sequences (at positions 257 to 273 and 302 to 306) and containing the four acidic residues, competed with the
binding of J18 protein to target cells and significantly inhibited (;60%) the penetration of parasites. This
peptide, generated by the juxtaposition of sequences that are separated by a hydrophobic stretch in the linear
molecule, appears to be mimicking a conformation-dependent cell-binding site of gp82. Experiments of
antibody competition with a set of 20-mer overlapping peptides mapped the epitope for 3F6, a monoclonal
antibody directed to gp82 that inhibits parasite invasion, to the sequence represented by peptide p3 (244 to
263), which has a partial overlap with the cell adhesion site.
Infection by Trypanosoma cruzi, a protozoan parasite that
causes Chagas disease in humans, is initiated by metacyclic
trypomastigotes which develop in and are transmitted by insect
vectors. Successful establishment of T. cruzi infection in mam-
malian hosts is critically dependent on parasite entry into tar-
get cells. Metacyclic parasite forms express a set of surface
glycoproteins that interact with mammalian cells (21, 22). One
of these molecules, a metacyclic-stage-specific 82-kDa glycop-
rotein (gp82), has been implicated in host cell invasion on the
basis that this process can be inhibited by native or recombi-
nant gp82 (21, 23) and by a monoclonal antibody (MAb 3F6)
that recognizes metacyclic forms but not the noninfective epi-
mastigote or other developmental stages of T. cruzi (28).
The metacyclic stage gp82 is an adhesion molecule that
binds to host cells in a receptor-mediated manner and triggers
Ca21 mobilization (7, 22), an event that is essential for parasite
penetration (3, 7, 15, 27, 32). Recent studies have indicated
that gp82 also induces the activation of metacyclic trypomas-
tigote protein tyrosine kinase (8) and an increase in the para-
site intracellular Ca21 concentration (22). The requirement of
these signal transduction events for T. cruzi infectivity has been
reported by several authors (15, 29, 33). Among other surface
glycoproteins in the size range of gp82, such as gp83 (14), gp85
(19), and Tc-85 (1), which are expressed in bloodstream or
tissue-culture derived trypomastigotes and which are impli-
cated in mammalian cell adhesion/invasion, gp83 has been
reported to signal through the mitogen-activated protein ki-
nase pathway to up regulate T. cruzi entry in macrophages (30).
Although gp82 is a member of a multigene family (2) that
shares a considerable degree of homology with members of the
gp85-trans-sialidase superfamily (5, 6, 24), it differs from these
molecules with regard to its adhesive properties. In tissue-
culture-derived trypomastigotes, a gp85 with affinity for fi-
bronectin (19), a laminin-binding Tc-85 (10, 11), a collagen-
and heparan sulfate-binding molecule of unknown sequence
designated penetrin (18), and an undefined heparin-binding
Ca21 signaling factor (4) have been reported. In contrast to all
of these other T. cruzi proteins that have been implicated in the
cell adhesion and invasion process, the metacyclic stage gp82
apparently does not bind to extracellular matrix components
(21).
The interaction of metacyclic trypomastigote gp82 with tar-
get cells is mediated by the peptide portion of the molecule,
the carbohydrate moiety playing no role in parasite invasion
(21, 23). The gp82 cell-binding site and the epitope for MAb
3F6 appear to be located in the central domain of the mole-
cule, but they have not been precisely defined. In the present
study, we sought to define these functional sites of gp82.
MATERIALS AND METHODS
Expression of gp82 recombinant proteins in pGEX-3. The construct J18,
comprising the full-length gp82 sequence in frame with the glutathione S-trans-
ferase (GST) gene of plasmid pGEX-3 (25), as well as the constructs J18a,
encoding 156 amino acids of the N-terminal domain, and J18b, which encodes
293 amino acids of the C-terminal domain, were prepared as previously de-
scribed (23). To obtain gp82 recombinants with various deletions in the central
domain of the molecule, novel restriction sites were first added to the gp82 gene
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by using the Quikchange Mutagenesis kit (Stratagene) as follows. Restriction
sites for XhoI (in boldface) and SalI (underlined) were inserted by using com-
plementary pairs of oligonucleotides corresponding to the gp82 coding strand
(59-ATTTCACTTGCCCGCTCGAGCGAGGAGCTGAAGACG-39, 59-GTCC
TCAGCACTTGGTCGACGCTGGATGCCTCCTTC-39, 59-CTGGTTGGACT
CCTCTCGAGTTCGCCAGCGGTGAC-39, 59-AAGGTCCATGACGGGTCG
ACATTCACGGGGTTTGGT-39) to prime amplification of plasmid J18 with
Pfu DNA polymerase (Stratagene) for 18 cycles of elongation at 68°C for 14 min
30 s per cycle. Reaction products were treated with DpnI to digest the input
plasmid templates then were purified and used to transform Escherichia coli.
Recovered plasmids were digested with BamHI (restriction site present in the
original preparation) plus either XhoI or SalI (restriction sites introduced by
PCR) to confirm the presence of the new sites. DNA samples were then sub-
jected to a new PCR cycle for the introduction of a second restriction site,
according to the protocol described above. The sequence flanked by the new sites
was deleted by digestion of plasmids with XhoI plus SalI and religation with T4
DNA ligase. To generate the gp82 mutants lacking the contiguous pairs of acidic
amino acids (see Fig. 2A), PCR amplification was carried out as described above
by using the primers 59-GGTGACGCGTGGATCTACCGTTCCGTGAAT-39
and 59-CTTGCCCGCCTGACCCTGAAGACGATCAAG-39. All constructs
were sequenced in order to ascertain that the desired deletion mutants were
obtained.
Purification of gp82 recombinant proteins. The recombinant GST fusion pro-
teins were purified from isopropyl-b-D-thiogalactopyranoside (IPTG)-induced E.
coli cells essentially as described (23), followed by electroelution (31). To assess
the purity of the proteins, the purified protein samples were analyzed in sodium
dodecyl sulfate–10% polyacrylamide gel electrophoresis gel by staining with
Coomassie blue and by immunoblotting as detailed (35). The purified recombi-
nant proteins appeared as bands of expected size. The bands of smaller size and
lower intensity seen in some preparations were probably products of protein
degradation and, as such, were recognized by MAb 3F6 (data not shown).
Synthetic peptides. Peptides were synthesized with the 9-fluorenylmethoxy
carbonyl methodology (12), by using an automated benchtop simultaneous mul-
tiple solid-phase peptide synthesizer (PSSM 8 system; Shimadzu, Tokyo, Japan).
The final peptides were deprotected in trifluoroacetic acid (TFA) and were
purified by semipreparative high-pressure liquid chromatography (HPLC) by
using an Econosil C18 column (10 m, 22.5 by 250 mm) and a two-solvent system
(TFA/H2O [1:1,000] and TFA/acetonitrile [ACN]/H2O [1:900:100]). The column
was eluted at a flow rate of 5 ml/min with a 10 (or 30) to 50 (or 60)% gradient
of solvent B over 30 or 45 min. Analytical HPLC was performed by using a binary
HPLC system from Shimadzu with a SPD-10AV Shimadzu UV-visual light
detector, coupled to an Ultrasphere C18 column (5 m, 4.6 by 150 mm) which was
eluted with solvent systems A1 (H3PO4/H2O, 1:1,000) and B1 (ACN/H2O/
H3PO4, 900:100:1) at a flow rate of 1.0 ml/min and a 10 to 80% gradient of B1
over 20 min. The HPLC column eluates were monitored by their absorbance at
220 nm. The molecular weight and purity of synthesized peptides were verified by
matrix-assisted laser desorption ionization–time of flight mass spectrometry
(TofSpec-E; Micromass).
Parasites, mammalian cells, and cell invasion assay. T. cruzi G (34) was used
in this study. Parasites were maintained by cyclic passage in mice and in axenic
cultures in liver infusion tryptose medium. Metacyclic trypomastigotes were
purified by passage through DEAE-cellulose columns, as described (35). HeLa
cells, the human-carcinoma-derived epithelial cells, were grown at 37°C in Dul-
becco’s minimal essential medium supplemented with 10% fetal calf serum
(FCS), streptomycin (100 mg/ml), and penicillin (100 U/ml) in a humidified 5%
CO2 atmosphere. Mammalian cell invasion assays were carried out as previously
described (35) by seeding 106 metacyclic forms onto each well of 24-well plates
containing 13-mm-diameter, round, glass coverslips coated with 2 3 105 HeLa
cells. After 3 h of incubation at 37°C, the duplicate coverslips were washed in
phosphate buffered saline (PBS), were pulsed for 1 min with water to lyse
externally associated parasites, and were washed three times with PBS. The
coverslips were fixed with methanol and were stained with Giemsa, and the
number of intracellular parasites was counted in a total of 500 cells.
Antibodies. MAb 3F6, directed to metacyclic trypomastigote gp82 (28), was
purified on a protein A Sepharose column. Immune sera to recombinant protein
J18a, containing the N-terminal gp82 sequence fused to GST, were prepared by
immunizing BALB/c mice with 4 doses of purified antigen (10 mg per mouse)
plus Al(OH)3 as adjuvant, at 2-week intervals. Ten days after the last immunizing
dose, the animals were bled and the sera were stored at 220°C. This antiserum
recognized all recombinant proteins analyzed in this study.
HeLa-cell-binding assay. HeLa cells (3 3 104), placed in 96-well microtiter
plates (Costar), were grown overnight at 37°C. After fixation with 4% parafor-
maldehyde in PBS, the cells were washed with PBS, were blocked with PBS
containing 10% FCS (FCS-PBS) for 1 h at room temperature, and were incu-
bated with varying concentrations of recombinant proteins in FCS-PBS. After 1 h
at 37°C, the cells were washed in PBS and were sequentially incubated for 1 h at
37°C with anti-J18a antibody diluted in FCS-PBS, and anti-mouse immunoglob-
ulin G conjugated to peroxidase. Following washes with PBS, the bound enzyme
was revealed by using o-phenylenediamine, as described (23).
Inhibition of binding of recombinant gp82 to HeLa cells with synthetic pep-
tides. The assay was performed as described above in 96-well microtiter plates,
with each well containing 3 3 104 HeLa cells. Cells were incubated for 1 h at
37°C with the recombinant protein J18 (10 mg/ml) in FCS-PBS, in the absence or
presence of individual synthetic peptides (200 mg/ml) representing the gp82
central domain. Bound antibody was detected as described above.
Competitive antibody binding between gp82 recombinant protein and syn-
thetic peptides. Wells of microtiter plates were coated with recombinant protein
J18b (1 mg/well), which contains the epitope for MAb 3F6. The plates were
blocked with FCS-PBS for 1 h at room temperature and were then incubated
with MAb 3F6 (1.6 mg/ml) in FCS-PBS, in the absence or presence of individual
synthetic peptides based on the gp82 central domain. After 1 h at 37°C, the plates
were washed in PBS and were incubated for 1 h at 37°C with anti-mouse
immunoglobulin G conjugated to peroxidase. Following washes in PBS, the
bound enzyme was revealed by using o-phenylenediamine as substrate.
RESULTS
Gp82 sequences containing acidic amino acid doublets are
involved in host-cell adhesion. To define the cell-binding site
FIG. 1. Schematic representation of the structure of T. cruzi gp82 recombinant proteins. Shown are the recombinant proteins fused to GST containing the full-length
gp82 sequence (J18) or lacking varying numbers of amino acid residues at different positions in the central domain. The constructs Del-4, Del-8, and Del 4/8 lack,
respectively, 15, 29, and 65 amino acid residues. Del-E and Del-D constructs are devoid of two glutamic and aspartic acid residues, respectively. Four acidic residues
are deleted in the construct Del-E/D.
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of gp82, known to be located in the central domain of the
molecule (23), binding assays were performed with recombi-
nant constructs lacking different sequences of that domain
(Fig. 1). Binding was assessed by incubating HeLa cells immo-
bilized on the bottom of microtiter plates with increasing con-
centrations of purified recombinant proteins. As shown in Fig.
2A, the construct J18, containing the full-length gp82 se-
quence, bound to HeLa cells in a dose-dependent and satura-
ble manner, whereas the construct Del-4/8, deleted of 65 res-
idues (amino acids 257 to 321), had a negligible binding
activity. Two other constructs with shorter deletions, Del-4
(257 to 271) and Del-8 (293 to 321), bound to HeLa cells, but
to a significantly lesser degree than did J18 (Fig. 2A), suggest-
ing that the portions deleted in these constructs participate in
cell adhesion. Since the presence of a pair of contiguous acidic
amino acids was a common feature of the deleted sequences in
constructs Del-4 and Del-8, we investigated whether these res-
idues played a role in cell adhesion by analyzing the binding
capacity of recombinant proteins lacking either one or both
pairs of acidic residues (Fig. 1). Removal of four residues in
the construct Del-E/D, namely the glutamic acid (259/260) and
aspartic acid (303/304) doublets, virtually abolished the cell
adhesion capacity (Fig. 2B). A significant decrease in binding
was also observed in Del-E, which lacks the glutamic acid pair,
whereas Del-D, devoid of the aspartic acid pair (303/304),
retained most of its binding capacity (Fig. 2B).
Consistent with the loss of cell-binding sites, the recombi-
nant proteins Del-4/8 and Del-E/D failed to inhibit the parasite
internalization, when added to HeLa cells in metacyclic trypo-
mastigote invasion assays, in contrast to what is seen with
construct J18 (Fig. 2C). The inhibitory effect of the recombi-
nant protein J18 was dose dependent: at concentrations of 80,
40, 20, and 10 mg/ml, the inhibition of HeLa cell invasion was
on the order of 80, 55, 40, and 15%, respectively.
A synthetic peptide formed by two noncontiguous gp82 se-
quences inhibits cell binding of gp82 and the parasite entry
into host cells. To further characterize the cell-binding site of
gp82, we performed inhibition binding experiments by incu-
bating HeLa cells with gp82 recombinant protein in the pres-
ence of individual peptides spanning the gp82 central domain
(Fig. 3). None of the peptides significantly inhibited the bind-
ing of recombinant J18 to HeLa cells (Fig. 4A), including the
peptides p4 and p8 which overlap with the sequences deleted in
the recombinant proteins Del-4 and Del-8, respectively. As our
data have shown that each of these sequences individually
contributes to gp82 adhesion to target cells, but more efficient
binding requires both sites (Fig. 2), we investigated the binding
efficacy of a composite of p4 and p8 sequences. A 22-mer
hybrid peptide p4/8 formed by a portion of p8 fused to p4, and
containing the four acidic amino acids, was synthesized (Fig. 3)
and was tested in experiments of inhibition of binding. We
observed a significantly diminished binding of recombinant J18
to HeLa cells in the presence of peptide p4/8 (Fig. 4B). When
added to HeLa cells in parasite invasion assays, in addition to
p4/8, the peptides p4 and p8 displayed inhibitory activity (Fig.
4C). To determine whether peptides with the same amino acid
composition of p4, p8, or p4/8, but with scrambled sequences,
had any effect on host cell invasion, the following peptides: p4*
(EWATIKVLTKSTERSLKSLL), p8* (GNMKWDVDNSRA
VDASAIYS), p4/8* (SKTRLLDTELDVTKSIEYWKIS), and
p4/8** (VSDLRITKDSYETKSKELWITL) were tested. Ex-
cepting p8*, which displayed some inhibitory activity, the
tested peptides did not significantly affect parasite entry into
HeLa cells, suggesting that binding is sequence dependent.
We have noted that peptides p4 and p8 were unable to affect
binding of gp82 to HeLa cells (Fig. 4B) but partially inhibited
parasite invasion (Fig. 4C). This apparent discrepancy could be
due to the fact that, in the binding assay, the peptides p4 and
p8 are competing with soluble recombinant gp82, whereas in
the invasion assay, the petides are competing with the gp82
FIG. 2. Binding of T. cruzi gp82 recombinant proteins to host cells and effect
on parasite invasion. In panels A and B, increasing concentrations of protein
were added to wells in enzyme-linked immunosorbent assay (ELISA) plates
containing adherent HeLa cells. After washes, cells were sequentially incubated
with anti-J18a antibodies and anti-mouse immunoglobulin conjugated to perox-
idase. The bound enzyme was revealed by using o-phenylenediamine as sub-
strate. In panel A, the assays were performed with the deletion mutants Del-4,
Del-8, and Del-4/8, lacking 15, 29, and 65 amino acid residues, respectively. Panel
B shows the results of experiments with the constructs Del-E, Del-D, and Del-
E/D lacking either or both of the glutamic acid and aspartic acid doublets. The
recombinant J18 containing the full-length gp82 sequence was used as control in
both assays. Representative results of one of four comparable experiments are
shown. The values are the means 6 the standard deviations (SD) of triplicates.
Panel C shows the result of an invasion assay in which the metacyclic forms were
incubated with HeLa cells in the presence of the indicated recombinant protein
at 80 mg/ml. After 3 h at 37°C, the cells were stained with Giemsa, and the
number of intracellular parasites were counted in a total of 500 cells. Values are
the means 6 SD of three assays performed in duplicate. O.D., optical density.
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molecule inserted in the parasite membrane, a circumstance
that poses a considerable constraint and which may restrict the
gp82 competitive capacity.
3F6 epitope has partial overlap with gp82 cell-binding se-
quence. In order to map the 3F6 epitope of gp82, we per-
formed assays of inhibition of antibody binding with the same
set of synthetic peptides used for inhibition of gp82 binding to
HeLa cells (Fig. 3). Microtiter plates coated with recombinant
protein J18b (amino acids 224 to 516) were incubated with
MAb 3F6 in the absence or presence of individual peptides at
200 mg/ml. Peptide p3 (244 to 263) inhibited binding of MAb
3F6 by ;90% (Fig. 5A). Lesser peptide p3 concentrations had
proportionally lower inhibitory effects (Fig. 5B). It should be
noted that there is an overlap of 10 amino acids between
peptide p3, representing the MAb 3F6 epitope, and peptide p4
containing the cell adhesion site (Fig. 3). This explains how
MAb inhibits the penetration of metacyclic trypomastigotes
into host cells (21). Although p3 contains the glutamic acid
pair also found in p4, these amino acids do not appear to be
part of 3F6 epitope. The reactivity of MAb 3F6 with the re-
combinant protein Del-4 or Del-E, which lacks the glutamic
acid doublet, was similar to that with J18 or with other con-
trols, such as recombinant proteins Del-8 and Del-D.
Gp82 does not bind to serum components or to extracellular
matrix proteins. Since the cell-binding assay was performed in
the presence of 10% FCS, in parallel experiments we deter-
mined whether the gp82 recombinant protein eventually
bound to serum components. J18, at the same concentrations
used in the HeLa cell-binding assays, was added to FCS-coated
plates, and the reaction proceeded according to the standard
protocol. No significant binding of J18 to FCS-coated plates
was observed. On the other hand, as cell adhesion molecules of
bloodstream-tissue culture trypomastigotes, such as Tc-85 and
gp85 (1, 19), reportedly bind to laminin or fibronectin (10, 19),
we investigated whether the metacyclic stage gp82 also bound
to these extracellular matrix proteins. Laminin or fibronectin,
at various concentrations, were added to microtiter plates
coated with recombinant J18, and the binding was assessed
with antibodies to laminin or fibronectin. Neither of these
proteins bound to recombinant gp82 (data not shown). These
results, added to the previous observation that gp82 does not
bind heparan sulfate or collagen (21), confirm the lack of
affinity of metacyclic trypomastigote gp82 for extracellular ma-
trix proteins.
DISCUSSION
We scrutinized the central domain of the metacyclic trypo-
mastigote surface glycoprotein gp82 in order to map the cell
adhesion site(s) of this stage-specific molecule, which has been
FIG. 3. Amino acid composition and position in T. cruzi gp82 central domain of synthetic peptides. Shown are the 20-mer peptides with an overlap of 10 residues
and 22-mer hybrid peptide p4/8 formed by two noncontiguous sequences containing parts of peptides p4 and p8.
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implicated in the process of parasite entry into mammalian
cells (21, 23). The results of experiments of cell adhesion with
deletion mutants of gp82 revealed two noncontiguous se-
quences as cell-binding sites. Deletion of either one of these
regions affected the binding capacity of recombinant gp82, and
deletion of the segment containing both regions virtually abol-
ished the cell adhesion property (Fig. 2A). The first region
encompasses amino acids 257 to 271 and the second region
encompasses amino acids 293 to 321. These results with the
deletion mutants are in agreement with a recent study with
insertion mutants of LamB, an integral outer membrane pro-
tein of E. coli (17). In that study, gp82-derived 20-mer pep-
tides, namely peptides p4 (254 to 273) and p8 (294 to 313),
which display a considerable overlap with the cell-binding re-
gions identified by the deletion mutants, were expressed as
fusions to the LamB protein in a region known to be exposed
on the protein surface (20). LamB carrying either peptide p4 or
p8 bound to HeLa cells in a dose-dependent fashion, whereas
the wild-type LamB, or LamB with an unrelated T. cruzi pep-
tide inserted in the same position, lacked binding activity (20).
The gp82 segments LTEELKTIKSVLSTW and NSASGDA
WIDDYRSVNAKVM, shared by peptides p4 and p8 and the
sequences removed from the Del-4 and Del-8 mutants, contain
several charged amino acids. Positively charged residues, in-
terspersed in the two segments, were also present elsewhere in
the gp82 central domain. However, the presence of doublets of
acidic residues was a characteristic of these segments (Fig. 3).
The relevance of these negatively charged residues in cell bind-
ing became evident in experiments with gp82 recombinant
proteins with these amino acids deleted. Deletion of both glu-
tamic acid and aspartic acid doublets effectively precluded
binding of gp82 to HeLa cells (Fig. 2B). The effect of removing
these acidic residues was comparable to that resulting from
deletion of all 65 amino acids comprising segments p4 and p8
(Figs. 2A and 2B).
Of the two cell adhesion sites, p4 appears to contribute more
FIG. 4. Inhibitory effect of hybrid peptide p4/8 on binding of T. cruzi gp82
recombinant proteins to HeLa cells and on parasite invasion. In panels A and B,
HeLa cells were incubated with the recombinant proteins J18 containing the
full-length gp82 sequence, in the absence or presence of the indicated peptide, at
200 mg/ml. Binding was measured by ELISA. Representative results of one of
three comparable experiments are shown. The values are the means 6 SD of
triplicates. (C) HeLa cells were incubated with metacyclic trypomastigotes in the
presence of the peptide. After 3 h at 37°C, the cells were stained with Giemsa,
and the number of intracellular parasites were counted in a total of 500 cells.
Values are the means 6 SD of three assays performed in duplicate. O.D., optical
density.
FIG. 5. Mapping of 3F6 epitope. Assays of inhibition of MAb 3F6 binding
were performed in microtiter plates coated with recombinant protein J18b, which
were incubated in the absence or presence of the indicated synthetic peptide at
200 mg/ml (A) or with varying concentrations of peptide p3 (B). Binding of MAb
3F6 was measured by ELISA. Representative results of one out of three exper-
iments are shown, and values are the means 6 SD of triplicate samples. O.D.,
optical density.
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to gp82 binding capacity than does p8. LamB carrying peptide
p4 binds more efficiently to HeLa cells than LamB carrying
peptide p8, and more bacteria expressing Lamb/p4 adhere to
HeLa cells than do bacteria expressing LamB/p8 (20). This is
consistent with our results showing that deletion of either the
p4 segment or the glutamic acid doublet had a greater effect on
the binding capacity of recombinant gp82 than deletion of the
p8 segment or the aspartic acid pair (Fig. 2). Of further sig-
nificance was the pattern of interaction of bacteria expressing
LamB/p4 or LamB/p8 with HeLa cells, which was found to
mimic the attachment of trypomastigotes to the edges of HeLa
cells (16). Another pertinent observation regarding the p4 cell-
binding site is its considerable overlap with peptide p3 (Fig. 3),
which contains the epitope for MAb 3F6 (Fig. 5), an antibody
that inhibits metacyclic trypomastigote entry into host cells
(21). Based on evidences that the 3F6-epitope is contiguous to
the cell-binding site of gp82, we presume that MAb 3F6 inter-
feres with parasite interaction with host cells by steric hin-
drance of gp82 cell-binding site.
One question raised during our study was whether the native
gp82 cell-binding site is conformation dependent. The cell
adhesion sites represented by peptides p4 and p8 are separated
in the primary sequence by a segment of 20 amino acids, of
which 12 are hydrophobic residues and only one is charged. As
each of these two sequences appeared to contribute to target
cell adhesion, but more efficient binding required both se-
quences, we envisaged a scenario in which the intervening
hydrophobic segment forms a loop in the protein interior in
order to allow the juxtaposition of p4 and p8 sequences on the
surface. Our finding that the hybrid peptide p4/8, formed by
parts of p4 and p8 sequences, inhibited binding of the full-
length gp82 recombinant protein, and parasite entry into target
cells (Fig. 4) gives support to our hypothesis that the actual
cell-binding site of gp82 depends on the conformation of this
region.
To our knowledge, this is the first characterization of a
cell-binding site of a T. cruzi surface glycoprotein. Other sur-
face molecules with adhesive properties, including those in the
size range of metacyclic trypomastigote gp82, have been de-
scribed in tissue-culture-derived trypomastigotes (10, 11, 14,
19), but their cell recognition sites have not been defined. As
these trypomastigote proteins, unlike the metacyclic gp82, bind
to one or more components of the extracellular matrix such as
laminin, fibronectin, heparan sulfate, and collagen, it is possi-
ble that their interaction with host cells is established through
matrix proteins.
The gp82 sequence shares a considerable degree of homol-
ogy with members of the gp85 family expressed in tissue cul-
ture or blood trypomastigotes (9, 11, 13, 26). Alignments by
BLAST algorithm have revealed 60 to 65% identities between
the central domain of metacyclic trypomastigote gp82 and the
C-terminal region glycoproteins of the gp85 family and 69%
identity with the C-terminal region of an amastigote surface
protein. However, the differences are also significant, including
substitutions of uncharged residues for lysine or arginine, sub-
stitutions of acidic residues for uncharged or positively charged
amino acids, and substitutions of amino acids with polar side
chains for those with nonpolar side chains and vice-versa. Of
note is that such substitutions can be found within sequences
identified as relevant for cell binding. Members of the trans-
sialidase family, which share ;40% identity with the metacy-
clic gp82 central region, showed differences which were more
extensive.
Invasion of mammalian cells by T. cruzi requires the activa-
tion of signal transduction pathways in the parasite and the
host cell (3, 7, 15, 27, 33). This requirement is fulfilled in
metacyclic trypomastigotes by the binding of gp82 to its host
cell receptor. In the target cells, gp82 triggers the signaling
cascade leading to Ca21 mobilization (7, 22), and it also signals
to the parasite interior, inducing the activation of protein try-
rosine kinase (8) and an increase in cytosolic free Ca21 con-
centration (22). By engaging this key molecule to interact with
host cells, the metacyclic trypomastigotes, which are deposited
by the insect on the skin of the host and then reach the sub-
jacent layer through the biting site, may have found the most
efficient way to enter cells.
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